Testing a new drug for high-risk bladder cancer
Treatments studied
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests a new drug called 9MW2821 for people with high-risk bladder cancer that hasn't grown into the bladder muscle. It's for those who have already tried other treatments that didn't work or who can't have standard therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You have tried at least one bladder treatment (like BCG or gemcitabine) that didn't work, or you cannot tolerate BCG.
- You have had a standard surgery (TURBT) in the last 6 weeks, and there is no cancer left in the surgery area.
- You have high-risk bladder cancer that has not spread into the bladder muscle, and you are not eligible for or do not want bladder removal surgery.
- Your heart, bone marrow, liver, and kidneys are working well enough, and you are in good general health (ECOG 0-1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This clinical trial tests a new drug, BH011, for people with high-risk, non-muscle-invasive bladder cancer that has come back or not responded to BCG therapy. The goal is to see if the drug is safe and works well when given directly into the bladder, as an alternative to bladder removal surgery.
This trial tests a new drug combination for women with advanced gynecologic tumors that have not responded to standard treatments. Participants receive 9MW2821 along with other anti-cancer drugs to see if the combination is safe and effective.
This trial tests a new drug, 9MW2821, against standard chemotherapy for people with advanced bladder cancer that has gotten worse after previous treatments. It aims to see if the new drug works better.
This trial is testing a new combination of two drugs (9MW2821 and toripalimab) against standard chemotherapy for people with advanced bladder cancer that has not been treated before. The goal is to see if this new approach works better at shrinking tumors or slowing the cancer's growth.
This trial tests a combination of a drug (DV) and BCG immunotherapy for people with high-risk, early-stage bladder cancer that has not spread into the muscle. The cancer must show a specific protein called HER2 on its cells.
This trial tests a new combination of two drugs—9MW2821 (an antibody-drug conjugate) and Toripalimab (an immunotherapy)—given before and after surgery for muscle-invasive or high-risk urothelial cancer that has not spread. The goal is to see if this combined treatment can improve outcomes.
Hear when a new Bladder Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.